Targeting ST18 for Therapeutic and Biomarker Development (G9705)

Target Name: ST18

NCBI ID: G9705

ST18

Targeting ST18 for Therapeutic and Biomarker Development

ST18 (ST18_HUMAN), also known as human ST18, is a protein that is expressed in various tissues of the human body. It is a member of the ST18 family, which includes several similar proteins that have been identified as potential drug targets or biomarkers.

The ST18 gene was first identified in 1997 and has since been widely studied. The protein encoded by the ST18 gene is a 21-kDa protein that is expressed in various tissues of the human body, including the liver, spleen, and lungs. It is also expressed in the testes and the placenta, and has been shown to be involved in several cellular processes, including cell adhesion, migration, and invasion.

One of the key features of the ST18 protein is its ability to interact with several different signaling pathways. For example, ST18 has been shown to interact with the TGF-β pathway, a well-established signaling pathway that is involved in regulation of cell growth, differentiation, and survival. Additionally, ST18 has been shown to interact with the PDGF pathway, a signaling pathway that is involved in the regulation of cell proliferation and survival.

These interactions between ST18 and signaling pathways highlight the potential of ST18 as a drug target or biomarker. By modulating the activity of these pathways, researchers may be able to develop new treatments for a variety of diseases.

One approach to targeting ST18 as a drug target is to develop small molecules that can modulate the activity of the TGF-β pathway. This can be done by identifying molecules that interact with ST18 and modulate its activity. For example, researchers have developed small molecules that can inhibit the activity of ST18 and prevent it from interacting with the TGF-β pathway. These molecules have been shown to be effective in animal models of several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Another approach to targeting ST18 as a drug target is to develop antibodies that can specifically recognize and target ST18. This can be done by identifying antibodies that recognize and bind to ST18 and can be used to block its activity in specific tissues or conditions. For example, researchers have developed antibodies that can specifically recognize ST18 and block its activity in the context of cancer. These antibodies have been shown to be effective in animal models of several diseases, including cancer.

In addition to its potential as a drug target, ST18 has also been identified as a potential biomarker. Its expression has been shown to be elevated in several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Additionally, ST18 has been shown to be expressed in tissues that are commonly used as biomarkers for these diseases, such as blood samples, saliva, and urine samples.

The potential of ST18 as a biomarker is of particular interest, as it may be possible to use it as a diagnostic tool for certain diseases. For example, by analyzing the expression of ST18 in blood samples from individuals with cancer, researchers may be able to determine the effectiveness of different treatments and monitor for any potential side effects.

In conclusion, ST18 is a protein that has been identified as potential drug target and biomarker. Its interactions with multiple signaling pathways make it an attractive target for small molecules and antibodies. As research continues to advance, it is likely that new treatments and biomarkers will be developed that can help improve the health and well-being of individuals with these diseases.

Protein Name: ST18 C2H2C-type Zinc Finger Transcription Factor

Functions: Repressor that binds to DNA sequences containing a bipartite element consisting of a direct repeat of the sequence 5'-AAAGTTT-3' separated by 2-9 nucleotides. Represses basal transcription activity from target promoters (By similarity). Inhibits colony formation in cultured breast cancer cells

The "ST18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ST18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets